IP Verse

Process For Manipulating The Level Of Glycan Content Of A Glycoprotein - EP3227454

The patent EP3227454 was granted to Amgen on Jan 29, 2020. The application was originally filed on Dec 1, 2015 under application number EP15816598A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3227454

AMGEN
Application Number
EP15816598A
Filing Date
Dec 1, 2015
Status
Granted And Under Opposition
Dec 27, 2019
Publication Date
Jan 29, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

D YOUNGOct 29, 2020D YOUNGADMISSIBLE
STRAWMANOct 29, 2020MEWBURN ELLISADMISSIBLE
WITHERS & ROGERS LLPWALLIN NICHOLASWRIGHT HOWARDOct 29, 2020BOULT WADE TENNANTADMISSIBLE
WITHERS & ROGERS LLPWALLIN NICHOLASWRIGHT HOWARDOct 29, 2020WILSONADMISSIBLE
CABINET LAVOIXOct 28, 2020LAVOIXADMISSIBLE
MAIWALDOct 28, 2020MAIWALDADMISSIBLE

Patent Citations (66) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONAU588819B
DESCRIPTIONEP0367566
DESCRIPTIONEP0460846
DESCRIPTIONUS2013303732
DESCRIPTIONUS4695623
DESCRIPTIONUS4897471
DESCRIPTIONUS4968607
DESCRIPTIONUS5075222
DESCRIPTIONUS5149792
DESCRIPTIONUS5272064
DESCRIPTIONUS5395760
DESCRIPTIONUS5610279
DESCRIPTIONUS5721121
DESCRIPTIONUS5767064
DESCRIPTIONUS5856296
DESCRIPTIONUS5981713
DESCRIPTIONUS6015938
DESCRIPTIONUS6096728
DESCRIPTIONUS6204363
DESCRIPTIONUS6235883
DESCRIPTIONUS6271349
DESCRIPTIONUS6337072
DESCRIPTIONUS6544424
DESCRIPTIONUS7420183
DESCRIPTIONUS8053238
DESCRIPTIONWO0136637
DESCRIPTIONWO0192337
DESCRIPTIONWO2008154014
DESCRIPTIONWO2008157247
DESCRIPTIONWO2012115874
DESCRIPTIONWO2012145682
DESCRIPTIONWO2013006479
DESCRIPTIONWO2013040444
DESCRIPTIONWO2013063298
DESCRIPTIONWO2013138159
DESCRIPTIONWO9410308
DESCRIPTIONWO9428391
DESCRIPTIONWO9701633
INTERNATIONAL-SEARCH-REPORTUS2012276631
INTERNATIONAL-SEARCH-REPORTWO2013114164
INTERNATIONAL-SEARCH-REPORTWO2013114245
OPPOSITIONEP1096017
OPPOSITIONUS2007231895
OPPOSITIONUS2012277165
OPPOSITIONUS5096816
OPPOSITIONUS6048728
OPPOSITIONUS6528286
OPPOSITIONUS7294484
OPPOSITIONUS9856502
OPPOSITIONWO2006026445
OPPOSITIONWO2006026447
OPPOSITIONWO2007070315
OPPOSITIONWO2008008360
OPPOSITIONWO2008055260
OPPOSITIONWO2008109410
OPPOSITIONWO2008128227
OPPOSITIONWO2010141855
OPPOSITIONWO2012149197
OPPOSITIONWO2013006479
OPPOSITIONWO2013114164
OPPOSITIONWO2013114245
OPPOSITIONWO2014150655
OPPOSITIONWO2014159488
OPPOSITIONWO2015011660
OPPOSITIONWO2015128314
OPPOSITIONWO2016089919

Non-Patent Literature (NPL) Citations (60) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BRADY ET AL., J AM SOC MASS SPECTRO, (2008), vol. 19, pages 502 - 509
DESCRIPTION- CHASIN ET AL., SOM. CELL MOLEC. GENET.,, (1986), vol. 12, pages 555 - 556
DESCRIPTION- DO; CHEN-KIANG, CYTOKINE GROWTH FACTOR REV., (2002), vol. 13, no. 1, pages 19 - 25
DESCRIPTION- FUREY, GEN. ENG. NEWS., (2002), vol. 22, no. 7, pages 62 - 63
DESCRIPTION- FURUKAWA; SATO, BIOCHIMICA ET BIOPHYSICA ACTA, (1999), vol. 1473, no. 1, pages 54 - 86
DESCRIPTION- GRAHAM ET AL., J. GEN. VIROL., (1977), vol. 36, page 59
DESCRIPTION- HÃ…KANSSON ET AL., STRUCTURE, (1999), vol. 7, pages 255 - 264
DESCRIPTION- HARBURY ET AL., NATURE, (1994), vol. 371, pages 80 - 83
DESCRIPTION- HARBURY ET AL., SCIENCE, (1993), vol. 262, pages 1401 - 1405
DESCRIPTION- HOSSLER ET AL., GLYCOBIOLOGY, (2009), vol. 19, no. 9, pages 936 - 949
DESCRIPTION- HOUDE ET AL., MOLECULAR AND CELLULAR PROTEOMICS, (2010), vol. 9, no. 8, pages 1716 - 1728
DESCRIPTION- KOLKEKAR ET AL., BIOCHEMISTRY, (1997), vol. 36, pages 10901 - 10909
DESCRIPTION- LIU ET AL., BIOTECHNOL. PROG., (2000), vol. 16, pages 425 - 434
DESCRIPTION- LOVEJOY ET AL., SCIENCE, (1993), vol. 259, pages 1288 - 1293
DESCRIPTION- MAISONPIERRE ET AL., SCIENCE, (1997), vol. 277, no. 5322, pages 55 - 60
DESCRIPTION- MATHER, Annals NY Acad. Sci., (1982), vol. 383, pages 44 - 68
DESCRIPTION- MATHER, BIOL. REPROD., (1980), vol. 23, pages 243 - 251
DESCRIPTION- RIIEGG; PYTELA, GENE, (1995), vol. 160, pages 257 - 262
DESCRIPTION- STETTLER ET AL., BIOTECHNOL BIOENG., (20061220), vol. 95, no. 6, pages 1228 - 1233
DESCRIPTION- The Cytokine Handbook, ACADEMIC PRESS, (2003), vol. I, 2
DESCRIPTION- URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, page 4216
DESCRIPTION- VOISARD ET AL., BIOTECHNOLOGY AND BIOENGINEERING, (2003), vol. 82, pages 751 - 765
INTERNATIONAL-SEARCH-REPORT- GRAMER M J ET AL, "Modulation of Antibody Galactosylation Through Feeding of Uridine, Manganese Chloride, and Galactose", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 108, no. 7, doi:10.1002/BIT.23075, ISSN 0006-3592, (201107), pages 1591 - 1602, (20110218), XP002688515 [A] 1 * the whole document *
OPPOSITION- Anonymous, "HyCloneâ„¢ media and supplements", GE Healthcare, (20151201), pages 1 - 4, XP093019487
OPPOSITION- Anonymous, "pH-Messungen verschiedener kommerzieller kommerzieller medien im bioreaktor mittels interner pH-Elektrode und externem BGA", Xell customized solutions for cell cultures, (20200608), XP055748354
OPPOSITION- BERGEMANN et al., "Chapter 9 : Production and downstream processing", Handbook of Therapeutic Antibodies, (20070000), pages 109 - 237, XP055748334
OPPOSITION- CELL ENGINEERING, "Bioreactor systems for producing antibody from Mammalian cells", CELL ENGINEERING, Mohamed Al-Rubeai, CELL ENGINEERING, vol 7: ANTIBODY EXPRESSION AND PRODUCTION, (20110000), vol. 7, pages 42 - 52, XP055748424
OPPOSITION- CHRISTIAN Gary D., "Chapter 3", Analytical Chemistry, (19940000), pages 65 - 114, XP055748269
OPPOSITION- Juan D. N. Diaz de Pool ,Sjoerd A. A. Van Den Berg ,Gonneke S. K. Pilgram,Bartholomeus E. P. B. Ballieux,Lucia A. J. Van Der Westerlaken, "Validation of the blood gas analyzer for pH measurements in IVF culture medium: Prevent suboptimal culture conditions", Plos One, (20181112), vol. 13, no. 11, page e0206707, XP055748363
OPPOSITION- KOMPALA et al., "Chapter 11: Optimization of high cell density perfusion bioreactors", Cell Culture Technology for Pharmaceutical and Cell-based Therapies, (20060000), pages 387 - 416, XP055650280
OPPOSITION- MÃœTHING et al., "Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24", Biotechnology and Bioengineering, (20030805), vol. 83, no. 3, pages 321 - 334, XP002576592
OPPOSITION- "Overview of the Profiler Platform", (20200813), URL: https://www.jmp.com/support/help/en/15.2/index.shtml#page/jmp/overview-of- the-profiler-platform.shtml#, XP055748417
OPPOSITION- POPP et al., "Development of a pre-glycoengineered CHO-K1 host cell line for the expressionof antibodies with enhanced Fc mediated effector function", mAbs, (20180000), vol. 10, no. 2, pages 290 - 303, XP055747992
OPPOSITION- POPP et al., "Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function", MABS, (20180000), vol. 10, no. 2, pages 290 - 303, XP055747992
OPPOSITION- "Powercho-2 CD", Safety Data Sheet, version 3.0, (20180829), XP055748408
OPPOSITION- SELLICK et al., "Optimizing CHO Cell Culture Conditions", Genetic Engineering & Biotechnology News, vol. 29, no. 17, (20091001), URL: https://www.genengnews.com/magazine/120/optimizing-cho-cell-culture-conditions, XP055748367
OPPOSITION- YANAGIDANI et al., "PURIFICATION AND CDNA CLONING OF GDP-L-FUC: N-ACETYL-BETA-D-GLUCOSAMINIDE: ALPHA1-6 FUCOSYLTRANSFERASE (ALPHA1-6 FUCT) FROM HUMAN GASTRIC CANCER MKN-45 CELLS", J. Biochem ., (19970000), vol. 121, pages 626 - 632, XP009003760
OPPOSITION- CROWELL et al., "Amino Acid and Manganese Supplementation Modulates the Glycosylation State of Erythropoietin in a CHO Culture System", Biotechnol. Bioeng., (20070000), vol. 96, doi:10.1002/bit.21141, pages 538 - 549, XP002457773
OPPOSITION- CROWELL et al., "Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system", Biotechnology and Bioengineering, (20060825), vol. 96, no. 3, pages 538 - 549, XP002454615
OPPOSITION- CROWELL et al., "Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system", Biotechnology and Bioengineering, (20070000), vol. 96, no. 3, pages 538 - 549, XP002457773
OPPOSITION- GRAMER et al., "Modulation of Antibody Galactosylation Through Feeding of Uridine, Manganese Chloride, and Galactose", Biotech & Bioeng, (20110000), vol. 108, no. 7, pages 1591 - 1602, XP002688515
OPPOSITION- GRAMER et al., "Modulation of Antibody Galactosylation Through Feeding of Uridine, Manganese Chloride, and Galactose", Biotechnology and Bioengineering, (20110215), vol. 108, no. 7, pages 1591 - 1602, XP002688515
OPPOSITION- ST AMAND et al., "Identification of manipulated variables for a glycosylation control strategy", Biotechnology and Bioengineering, (20140000), vol. 111, no. 10, pages 1957 - 1970, XP055190261
OPPOSITION- ROUILLER ET AL., "Modulation of mAb quality attributes using microliter scale fed-batch cultures", Biotechnol Prog, (20140428), pages 1 - 36, XP055748320
OPPOSITION- YUK et al., "Effects of copper on CHO cells: Cellular requirements and product quality considerations", American Institute of Chemical Engineers, (20141024), vol. 31, no. 1, pages 226 - 238, XP055669449
OPPOSITION- YUK et al., "Effects of copper on CHO cells: Cellular requirements and product quality considerations", Biotechnol. Prog., (20150000), vol. 31, no. 1, pages 226 - 238, XP055669449
OPPOSITION- YUK et al., "Effects of copper on CHO cells: Cellular requirements and product quality considerations", Biotechnol. Prog., vol. 31, doi:10.1002/btpr.2004, (20141024), pages 226 - 238, XP055669449
OPPOSITION- HOSSLER et al., "Protein Glycosylation Control in Mammalian Cell Culture: Past Precedents and Contemporary Prospects", Adv Biochem Engin/Biotechnol, (20120000), vol. 127, pages 187 - 219, XP055679442
OPPOSITION- Sung Kwan Yoon; Yong-Ho Ahn; Myeong Hyeon Jeong, "Effect of culture temperature on follicle-stimulating hormone production by Chinese hamster ovary cells in a perfusion bioreactor", Appl. Microbiol Biotechnol, (20070503), vol. 76, no. 1, pages 83 - 89, XP019538802
OPPOSITION- LEITO et al., "Estimation of uncertainty in routine pH measurement", Accreditation and Quality Assurance, (20020000), vol. 7, pages 242 - 249, XP055748398
OPPOSITION- BUTLER et al., "Optimisation of the Cellular Metabolism of Glycosylation for Recombinant Proteins Produced by Mammalian Cell Systems", Cytotechnology, (20060000), vol. 50, pages 57 - 76, XP019393897
OPPOSITION- KUMAR et al., "Proliferation control strategies to improve productivity and survival during CHO based production culture; A summary of recent methods employed and the effects of proliferation control in product secreting CHO cell lines", Cytotechnology, (20070000), vol. 53, pages 33 - 46, XP019499816
OPPOSITION- KARAIVANOVA et al., "Characterization and Purification of Fucosyltransferases from the Cytosol of Rat Colon", Int. J. Biochem. Cell Biol., (19960000), vol. 28, no. 2, pages 165 - 174, XP055748000
OPPOSITION- Mohammad Adil; Agarabi Cyrus; Rogstad Sarah; DiCioccio Elizabeth; Brorson Kurt; Ashraf Muhammad; Faustino Patrick J.; Madhavarao Chikkathur N., "An ICP-MS platform for metal content assessment of cell culture media and evaluation of spikes in metal concentration on the quality of an IgG3:κ monoclonal antibody during production", Journal of Pharmaceutical and Biomedical Analysis, Elsevier B.V., AMSTERDAM, NL, AMSTERDAM, NL , (20180910), vol. 162, doi:10.1016/j.jpba.2018.09.008, ISSN 0731-7085, pages 91 - 100, XP085509497
OPPOSITION- STRUPPE et al., "Occurence of GDP-L-fucose: @b-N-acetylglucosamine (Fuc to Asn-linked GlcNAc) @a1,6-fucosyltransferases in porcine, sheep, bovine, rabbit and chicken tissues", Biochimica et Biophysica Acta, (20000000), vol. 1475, no. 3, pages 360 - 368, XP004276658
OPPOSITION- KAMINSKA et al., "Purification and characterization of GDP-L-Fuc: N-acetyl beta-D-glucosaminide alpha1 leads to 6fucosyltransferase from human blood platelets", Glycoconjugate Journal, (19980000), vol. 15, no. 8, pages 783 - 788, XP002526140
OPPOSITION- KAMINSKA et al., "Purification and characterization of GDP-L-Fuc: N-acetyl beta-D-glucosaminide alpha1 leads to 6fucosyltransferase from human blood platelets", Glycoconjugate Journal, (19980000), vol. 15, pages 783 - 788, XP002526140
OPPOSITION- HOSSLER et al., "Optimal and consistent protein glycosylation in mammalian cell culture", Glycobiology, (20090000), vol. 19, no. 9, pages 936 - 949, XP055112498
OPPOSITION- Hossler P; Khattak S F; Li Z J, "Optimal and consistent protein glycosylation in mammalian cell culture", Glycobiology, (20090603), vol. 19, no. 9, pages 936 - 949, XP055112498
OPPOSITION- SCHIRRMANN et al., "Production systems for recombinant antibodies", Front Biosci, (20080501), vol. 13, pages 4576 - 4594, XP055748343

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents